drugset
drugset / Trial / NCT02572453

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

NCT02572453 ↗

Phase 2 Terminated 25 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies how well onalespib works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previous treatment (refractory) or that has returned after a period of improvement (recurrent). Onalespib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2016-04-04
Primary completion
2021-03-18
Completion
2021-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Onalespib Small molecule 160 mg/m2 Intravenous

Indications

anaplastic large cell lymphoma diffuse large B-cell lymphoma mantle cell lymphoma